ESMO25: The changing landscape of rare oncology, with Jan Kirsten

There is much data shared at European Society for Medical Oncology (ESMO) Annual Meetings in cancers of the lung, breast, bladder, and colon, for example. But this year, there was presentation of meaningful data within the rare oncology space, also.

So it was that pharmaphorum sat down with Jan Kirsten, global head of the rare tumour business for SpringWorks Therapeutics – a healthcare company of Merck KGaA – to discuss mirdametinib’s application as treatment of symptomatic, inoperable plexiform neurofibromas (PN), as well as rare cancers and the 2025 Congress more generally.

Watch this and other conversations from Berlin for ESMO 2025 here.